TCT 2019: Five-Year PARTNER 2A Results Support TAVR In Most Intermediate Risk Patients

03 Oct 2019

A new update from the PARTNER 2A trial shows transcatheter aortic valve replacement with Edwards Lifesciences' Sapien XT yields similar outcomes to valve surgery in intermediate risk patients.

Aerial cityscape view of San Francisco, California, USA - Image — • Source: shutterstock.com

TCT 2019: Five-Year PARTNER 2A Results Support TAVR In Most Intermediate Risk Patients

More from Clinical Trials

More from R&D